[go: up one dir, main page]

EA200800144A1 - МОДИФИКАЦИИ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ - Google Patents

МОДИФИКАЦИИ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ

Info

Publication number
EA200800144A1
EA200800144A1 EA200800144A EA200800144A EA200800144A1 EA 200800144 A1 EA200800144 A1 EA 200800144A1 EA 200800144 A EA200800144 A EA 200800144A EA 200800144 A EA200800144 A EA 200800144A EA 200800144 A1 EA200800144 A1 EA 200800144A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cspcna
isoforms
modifications
application
disclosed
Prior art date
Application number
EA200800144A
Other languages
English (en)
Other versions
EA013109B1 (ru
Inventor
Дерек Дж. Хоуэлз
Роберт Дж. Хикки
Линда Х. Малкас
Original Assignee
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн filed Critical Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн
Publication of EA200800144A1 publication Critical patent/EA200800144A1/ru
Publication of EA013109B1 publication Critical patent/EA013109B1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Insulating Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Раскрывают способы и композиции для выявления присутствия csPCNA изоформы посредством идентифицирования одной или нескольких посттрансляционных модификаций. Раскрывают способы идентифицирования csPCNA изоформы через посредство посттрансляционных модификаций, включая уровни метилэстерификации.
EA200800144A 2005-06-27 2006-06-26 МОДИФИКАЦИИ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ EA013109B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69415905P 2005-06-27 2005-06-27
PCT/US2006/024774 WO2007002574A2 (en) 2005-06-27 2006-06-26 Cspcna isoform modifications and uses thereof

Publications (2)

Publication Number Publication Date
EA200800144A1 true EA200800144A1 (ru) 2008-06-30
EA013109B1 EA013109B1 (ru) 2010-02-26

Family

ID=37116243

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800144A EA013109B1 (ru) 2005-06-27 2006-06-26 МОДИФИКАЦИИ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ

Country Status (12)

Country Link
US (2) US7932023B2 (ru)
EP (1) EP1899373B1 (ru)
JP (1) JP5090344B2 (ru)
CN (1) CN101258161A (ru)
AT (1) ATE504598T1 (ru)
AU (1) AU2006261856B2 (ru)
BR (1) BRPI0611703A2 (ru)
CA (1) CA2612695A1 (ru)
DE (1) DE602006021178D1 (ru)
EA (1) EA013109B1 (ru)
HK (1) HK1112928A1 (ru)
WO (1) WO2007002574A2 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007098415A2 (en) * 2006-02-17 2007-08-30 Indiana University Research And Technology Corporation Peptide based inhibition of capcna protein-protein interactions in cancer
CA2732737C (en) 2008-07-24 2019-03-05 Indiana University Research And Technology Corporation Cancer peptide therapeutics
WO2011044372A1 (en) * 2009-10-09 2011-04-14 Indiana University Research And Technology Corporation Pcna methyltransferase
US8455200B2 (en) 2009-10-15 2013-06-04 Traxxsson, Llc Measurement of PKA for cancer detection
JP2014511839A (ja) * 2011-03-23 2014-05-19 インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレイション 抗癌治療薬
US10420840B2 (en) * 2015-04-10 2019-09-24 Rll, Llc Anticancer therapeutic agents
TW202411650A (zh) * 2018-02-01 2024-03-16 美商再生元醫藥公司 治療性單株抗體之品質屬性的定量及模型化

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7294471B2 (en) * 2002-02-27 2007-11-13 Cskeys, Llc Method for purifying cancer-specific proliferating cell nuclear antigen

Also Published As

Publication number Publication date
EP1899373B1 (en) 2011-04-06
US20110195510A1 (en) 2011-08-11
AU2006261856B2 (en) 2012-07-05
JP2008547034A (ja) 2008-12-25
WO2007002574A3 (en) 2007-05-03
HK1112928A1 (en) 2008-09-19
ATE504598T1 (de) 2011-04-15
DE602006021178D1 (de) 2011-05-19
WO2007002574A2 (en) 2007-01-04
AU2006261856A1 (en) 2007-01-04
JP5090344B2 (ja) 2012-12-05
CA2612695A1 (en) 2007-01-04
CN101258161A (zh) 2008-09-03
US20090061432A1 (en) 2009-03-05
EP1899373A2 (en) 2008-03-19
EA013109B1 (ru) 2010-02-26
BRPI0611703A2 (pt) 2011-12-20
US7932023B2 (en) 2011-04-26

Similar Documents

Publication Publication Date Title
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
NO20071127L (no) Triazoloftalaziner
EA202091230A2 (ru) Антагонисты активин-actrii и их применения для повышения уровней эритроцитов
CR20150088A (es) Anticuerpos anti-notch1 nrr
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
DE602006015793D1 (de) Proteolipidmembran und lipidmembranen-biosensor
AR057253A1 (es) Anticuerpos anti-ox40l y metodos que los utilizan
CO6571886A2 (es) Antagonistas de pcsk9
EA200800144A1 (ru) МОДИФИКАЦИИ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
WO2010031056A3 (en) Methods and compositions for modulating ire1, src, and abl activity
EA201100306A1 (ru) Производные циклогексиламида и их применение в качестве антагонистов рецептора crf-1
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
ATE498134T1 (de) Nachweis von staphylococcus
MY173526A (en) Novel anti-?5?1 antibodies and uses thereof
DK2021794T3 (da) Anvendelse af protein S100A 12 som en markør for colorektal cancer
MX373170B (es) Variantes de la familia il-1.
EA200801676A1 (ru) Комбинация производных триазина и сенсибилизаторов инсулина
NO20084320L (no) Antistoffer mot EGFL7 og fremgangsmater for anvendelse av disse
EP1960318A4 (en) ANTI-CORROSION COMPOSITIONS FOR THE TREATMENT OF CURED CONCRETE STRUCTURES
ATE549638T1 (de) 13c-mr-bildgebung oder spektroskopie von zelltod
CY1112877T1 (el) Μεταλλαγματα αυξητικου παραγoντα υψηλης δραστικοτητας
SG131082A1 (en) Fabp4 as marker for a toxic effect
EA201100672A1 (ru) Гербицидные композиции, содержащие дифлюфеникан и als-ингибиторы
ATE542796T1 (de) N-sulfonylcarboximidamidverbindungen als apoptosepromotoren

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU